The medicinal chemistry of novel iron Chelators for the treatment of cancer

Current Topics in Medicinal Chemistry

Volumn 11, Issue 5, 2011, Pages 483-499

  Kovacevic, Zaklina ^a   Kalinowski, Danuta S ^a   Lovejoy, David B ^a   Yu, Yu ^a   Rahmanto, Yohan Suryo ^a   Sharpe, Phillip C ^b   Bernhardt, Paul V ^b   Richardson, Des R ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Cancer; Chelators; Complexes; Iron; Thiosemicarbazones

Indexed keywords

2 BENZOYLPYRIDINE THIOSEMICARBAZONE; 2 HYDROXY 1 NAPHTHYLALDEHYDE; 3 AMINOPICOLINALDEHYDE THIOSEMICARBAZONE; 3 AMINOPYRIDIN 2 CARBOXALDEHYDE THIOSEMICARBAZONE; AROYLHYDRAZONE; BENZOYLPYRIDINE THIOSEMICARBAZONE; CARBOPLATIN; CURCUMIN; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLOPHOSPHAMIDE; DEFEROXAMINE; DI 2 PYRIDYLKETONE ISONICOTINOYL HYDRAZONE; DI 2 PYRIDYLKETONE THIOSEMICARBAZONE; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; HYDRAZONE DERIVATIVE; HYPOXIA INDUCIBLE FACTOR 1; IRON; IRON CHELATING AGENT; METAL COMPLEX; MITOXANTRONE; NSC 73306; PLACEBO; PYRIDOXAL ISONICOTINOYL HYDRAZONE; SILIBININ; THIOSEMICARBAZONE; THIOSEMICARBAZONE DERIVATIVE; THIOTEPA; TOPOTECAN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER RESISTANCE; CANCER THERAPY; CAUSE OF DEATH; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TARGETING; DRUG WITHDRAWAL; EYE TOXICITY; HUMAN; IRON ABSORPTION; IRON INTAKE; IRON METABOLISM; IRON TRANSPORT; KIDNEY CARCINOMA; LEUKOPENIA; LUNG CARCINOMA; LUNG NON SMALL CELL CANCER; METALLATION; METHEMOGLOBINEMIA; NEOPLASM; NEUTROPENIA; NONHODGKIN LYMPHOMA; NONHUMAN; STRUCTURE ACTIVITY RELATION;

ANTINEOPLASTIC AGENTS; CELL PROLIFERATION; CHELATION THERAPY; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; IRON; IRON CHELATING AGENTS; NEOPLASMS;

EID: 79952752677     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/156802611794785190     Document Type: Article

References (139)

1. Chua, A. C.; Graham, R. M.; Trinder, D.; Olynyk, J. K. The regulation of cellular iron metabolism. Crit. Rev. Clin. Lab. Sci., 2007, 44, 413-459.
2. De Domenico, I.; McVey Ward, D.; Kaplan, J. Regulation of iron acquisition and storage: consequences for iron-linked disorders. Nat. Rev. Mol. Cell Biol., 2008, 9, 72-81.
3. Dunn, L. L.; Rahmanto, Y. S.; Richardson, D. R. Iron uptake and metabolism in the new millennium. Trends Cell Biol., 2007, 17, 93-100.
4. Cairo, G.; Recalcati, S. Iron-regulatory proteins: molecular biology and pathophysiological implications. Expert Rev. Mol. Med., 2007, 9, 1-13.
5. Hentze, M. W.; Kuhn, L. C. Molecular control of vertebrate iron metabolism: mRNA-based regulatory circuits operated by iron, nitric oxide, and oxidative stress. Proc. Natl. Acad. Sci. USA, 1996, 93, 8175-8182.
6. Eisenstein, R. S. Iron regulatory proteins and the molecular control of mammalian iron metabolism. Annu. Rev. Nutr., 2000, 20, 627-662.
7. Thompson, J. Vitamins, minerals and supplements. 7: Minerals. Commun. Pract., 2007, 80, 38-40.
8. Shayeghi, M.; Latunde-Dada, G. O.; Oakhill, J. S.; Laftah, A. H.; Takeuchi, K.; Halliday, N.; Khan, Y.; Warley, A.; McCann, F. E.; Hider, R. C.; Frazer, D. M.; Anderson, G. J.; Vulpe, C. D.; Simpson, R. J.; McKie, A. T. Identification of an intestinal heme transporter. Cell, 2005, 122, 789-801.
9. Andrews, N. C. When is a heme transporter not a heme transporter? When it's a folate transporter. Cell Metab., 2007, 5, 5-6.
10. Gleeson, F.; Ryan, E.; Barrett, S.; Russell, J.; Kelleher, B.; Crowe, J. Duodenal Dcytb and hephaestin mRNA expression are not significantly modulated by variations in body iron homeostasis. Blood Cells Mol. Dis., 2005, 35, 303-308.
11. Latunde-Dada, G. O.; Van der Westhuizen, J.; Vulpe, C. D.; Anderson, G. J.; Simpson, R. J.; McKie, A. T. Molecular and functional roles of duodenal cytochrome B (Dcytb) in iron metabolism. Blood Cells Mol. Dis., 2002, 29, 356-360.
12. Gunshin, H.; Allerson, C. R.; Polycarpou-Schwarz, M.; Rofts, A.; Rogers, J. T.; Kishi, F.; Hentze, M. W.; Rouault, T. A.; Andrews, N. C.; Hediger, M. A. Iron-dependent regulation of the divalent metal ion transporter. FEBS Lett., 2001, 509, 309-316.
13. Fleming, M. D.; Trenor, C. C., 3rd; Su, M. A.; Foernzler, D.; Beier, D. R.; Dietrich, W. F.; Andrews, N. C. Microcytic anaemia mice have a mutation in Nramp2, a candidate iron transporter gene. Nat. Genet., 1997, 16, 383-386.
14. Donovan, A.; Lima, C. A.; Pinkus, J. L.; Pinkus, G. S.; Zon, L. I.; Robine, S.; Andrews, N. C. The iron exporter ferroportin/Slc40a1 is essential for iron homeostasis. Cell Metab., 2005, 1, 191-200.
15. De Domenico, I.; Ward, D. M.; Musci, G.; Kaplan, J. Evidence for the multimeric structure of ferroportin. Blood, 2007, 109, 2205-2209.
16. Vulpe, C. D.; Kuo, Y. M.; Murphy, T. L.; Cowley, L.; Askwith, C.; Libina, N.; Gitschier, J.; Anderson, G. J. Hephaestin, a ceruloplasmin homologue implicated in intestinal iron transport, is defective in the sla mouse. Nat. Genet., 1999, 21, 195-199.
17. Chen, H.; Attieh, Z. K.; Su, T.; Syed, B. A.; Gao, H.; Alaeddine, R. M.; Fox, T. C.; Usta, J.; Naylor, C. E.; Evans, R. W.; McKie, A. T.; Anderson, G. J.; Vulpe, C. D. Hephaestin is a ferroxidase that maintains partial activity in sex-linked anemia mice. Blood, 2004, 103, 3933-3939.
18. Richardson, D. R. Iron chelators as therapeutic agents for the treatment of cancer. Crit. Rev. Oncol. Hematol., 2002, 42, 267-281.
19. Kawabata, H.; Yang, R.; Hirama, T.; Vuong, P. T.; Kawano, S.; Gombart, A. F.; Koeffler, H. P. Molecular cloning of transferrin receptor 2. A new member of the transferrin receptor-like family. J. Biol. Chem., 1999, 274, 20826-20832.
20. Kawabata, H.; Fleming, R. E.; Gui, D.; Moon, S. Y.; Saitoh, T.; O'Kelly, J.; Umehara, Y.; Wano, Y.; Said, J. W.; Koeffler, H. P. Expression of hepcidin is down-regulated in TfR2 mutant mice manifesting a phenotype of hereditary hemochromatosis. Blood, 2005, 105, 376-381.
21. Aisen, P. Transferrin receptor 1. Int. J. Biochem. Cell Biol., 2004, 36, 2137-2143.
22. Brinkmann, M.; Teuffel, R.; Laham, N.; Ehrlich, R.; Decker, P.; Lemonnier, F. A.; Pascolo, S. Expression of iron transport proteins divalent metal transporter-1, Ferroportin-1, HFE and transferrin receptor-1 in human monocyte-derived dendritic cells. Cell Biochem. Funct., 2007, 25, 287-296.
23. Klausner, R. D.; Ashwell, G.; van Renswoude, J.; Harford, J. B.; Bridges, K. R. Binding of apotransferrin to K562 cells: explanation of the transferrin cycle. Proc. Natl. Acad. Sci. USA, 1983, 80, 2263-2266.
24. Ohgami, R. S.; Campagna, D. R.; Greer, E. L.; Antiochos, B.; McDonald, A.; Chen, J.; Sharp, J. J.; Fujiwara, Y.; Barker, J. E.; Fleming, M. D. Identification of a ferrireductase required for efficient transferrin-dependent iron uptake in erythroid cells. Nat. Genet., 2005, 37, 1264-1269.
25. Kalinowski, D. S.; Richardson, D. R. The evolution of iron chelators for the treatment of iron overload disease and cancer. Pharmacol. Rev., 2005, 57, 547-83.
26. Breuer, W.; Shvartsman, M.; Cabantchik, Z. I. Intracellular labile iron. Int. J. Biochem. Cell Biol., 2008, 40, 350-354.
27. Rouault, T. A. Post-transcriptional regulation of human iron metabolism by iron regulatory proteins. Blood Cells Mol. Dis., 2002, 29, 309-314.
28. Kato, J.; Kobune, M.; Ohkubo, S.; Fujikawa, K.; Tanaka, M.; Takimoto, R.; Takada, K.; Takahari, D.; Kawano, Y.; Kohgo, Y.; Niitsu, Y. Iron/IRP-1-dependent regulation of mRNA expression for transferrin receptor, DMT1 and ferritin during human erythroid differentiation. Exp. Hematol., 2007, 35, 879-887.
29. Zoller, H.; Theurl, I.; Koch, R.; Kaser, A.; Weiss, G. Mechanisms of iron mediated regulation of the duodenal iron transporters divalent metal transporter 1 and ferroportin 1. Blood Cells Mol. Dis., 2002, 29, 488-497.
30. De Domenico, I.; Ward, D. M.; Langelier, C.; Vaughn, M. B.; Nemeth, E.; Sundquist, W. I.; Ganz, T.; Musci, G.; Kaplan, J. The molecular mechanism of hepcidin-mediated ferroportin downregulation. Mol. Biol. Cell, 2007, 18, 2569-2578.
31. Chaston, T.; Chung, B.; Mascarenhas, M.; Marks, J.; Patel, B.; Srai, S. K.; Sharp, P. Evidence for differential effects of hepcidin in macrophages and intestinal epithelial cells. Gut, 2008, 57, 374-382.
32. Nemeth, E.; Ganz, T. Regulation of iron metabolism by hepcidin. Annu. Rev. Nutr., 2006, 26, 323-342.
33. Atanasiu, V.; Manolescu, B.; Stoian, I. Hepcidin--central regulator of iron metabolism. Eur. J. Haematol., 2007, 78, 1-10.
34. Mena, N. P.; Esparza, A.; Tapia, V.; Valdes, P.; Nunez, M. T. Hepcidin inhibits apical iron uptake in intestinal cells. Am. J. Physiol. Gastrointest Liver Physiol., 2008, 294, G192-198.
35. Yu, Y.; Wong, J.; Lovejoy, D. B.; Kalinowski, D. S.; Richardson, D. R. Chelators at the cancer coalface: desferrioxamine to triapine and beyond. Clin. Cancer Res., 2006, 12, 6876-6883.
36. Le, N. T.; Richardson, D. R. The role of iron in cell cycle progression and the proliferation of neoplastic cells. Biochim. Biophys. Acta, 2002, 1603, 31-46.
37. Elford, H. L.; Freese, M.; Passamani, E.; Morris, H. P. Ribonucleotide reductase and cell proliferation. I. Variations of ribonucleotide reductase activity with tumor growth rate in a series of rat hepatomas. J. Biol. Chem.,1970, 245, 5228-5233.
38. Green, D. A.; Antholine, W. E.; Wong, S. J.; Richardson, D. R.; Chitambar, C. R. Inhibition of malignant cell growth by 311, a novel iron chelator of the pyridoxal isonicotinoyl hydrazone class: effect on the R2 subunit of ribonucleotide reductase. Clin. Cancer Res., 2001, 7, 3574-3579.
39. Nyholm, S.; Mann, G. J.; Johansson, A. G.; Bergeron, R. J.; Graslund, A.; Thelander, L. Role of ribonucleotide reductase in inhibition of mammalian cell growth by potent iron chelators. J. Biol. Chem., 1993, 268, 26200-26205.
40. Le, N. T.; Richardson, D. R. Iron chelators with high antiproliferative activity up-regulate the expression of a growth inhibitory and metastasis suppressor gene: a link between iron metabolism and proliferation. Blood, 2004, 104, 2967-2975.
41. Hollstein, M.; Sidransky, D.; Vogelstein, B.; Harris, C. C. p53 mutations in human cancers. Science, 1991, 253, 49-53.
42. Fukuchi, K.; Tomoyasu, S.; Watanabe, H.; Kaetsu, S.; Tsuruoka, N.; Gomi, K. Iron deprivation results in an increase in p53 expression. Biol. Chem. Hoppe Seyler, 1995, 376, 627-630.
43. Gao, J.; Richardson, D. R. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents, IV: The mechanisms involved in inhibiting cell-cycle progression. Blood, 2001, 98, 842-850.
44. Liang, S. X.; Richardson, D. R. The effect of potent iron chelators on the regulation of p53: examination of the expression, localization and DNA-binding activity of p53 and the transactivation of WAF1. Carcinogenesis, 2003, 24, 1601-1614.
45. Pahl, P. M.; Reese, S. M.; Horwitz, L. D. A lipid-soluble iron chelator alters cell cycle regulatory protein binding in breast cancer cells compared to normal breast cells. J. Exp. Ther. Oncol., 2007, 6, 193-200.
46. Fu, D.; Richardson, D. R. Iron chelation and regulation of the cell cycle: 2 mechanisms of posttranscriptional regulation of the universal cyclin-dependent kinase inhibitor p21CIP1/WAF1 by iron depletion. Blood, 2007, 110, 752-761.
47. el-Deiry, W. S.; Tokino, T.; Velculescu, V. E.; Levy, D. B.; Parsons, R.; Trent, J. M.; Lin, D.; Mercer, W. E.; Kinzler, K. W.; Vogelstein, B. WAF1, a potential mediator of p53 tumor suppression. Cell, 1993, 75, 817-825.
48. Harper, J. W.; Adami, G. R.; Wei, N.; Keyomarsi, K.; Elledge, S. J. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell, 1993, 75, 805-816.
49. Xiong, Y.; Hannon, G. J.; Zhang, H.; Casso, D.; Kobayashi, R.; Beach, D. p21 is a universal inhibitor of cyclin kinases. Nature, 1993, 366, 701-704.
50. Weiss, R. H. p21Waf1/Cip1 as a therapeutic target in breast and other cancers. Cancer Cell, 2003, 4, 425-429.
51. Thaler, S.; Hahnel, P. S.; Schad, A.; Dammann, R.; Schuler, M. RASSF1A mediates p21Cip1/Waf1-dependent cell cycle arrest and senescence through modulation of the Raf-MEK-ERK pathway and inhibition of Akt. Cancer Res., 2009, 69, 1748-1757.
52. Darnell, G.; Richardson, D. R. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents III: the effect of the ligands on molecular targets involved in proliferation. Blood, 1999, 94, 781-792.
53. Le, N. T.; Richardson, D. R. Potent iron chelators increase the mRNA levels of the universal cyclin-dependent kinase inhibitor p21(CIP1/WAF1), but paradoxically inhibit its translation: a potential mechanism of cell cycle dysregulation. Carcinogenesis, 2003, 24, 1045-1058.
54. Tvrdik, D.; Dundr, P.; Povysil, C.; Pytlik, R.; Plankova, M. Upregulation of p21WAF1 expression is mediated by Sp1/Sp3 transcription factors in TGFbeta1-arrested malignant B cells. Med. Sci. Monit., 2006, 12, BR227-234.
55. Wajapeyee, N.; Somasundaram, K. Cell cycle arrest and apoptosis induction by activator protein 2alpha (AP-2alpha) and the role of p53 and p21WAF1/CIP1 in AP-2alpha-mediated growth inhibition. J. Biol. Chem., 2003, 278, 52093-52101.
56. Sherr, C. J. Mammalian G1 cyclins and cell cycle progression. Proc. Assoc. Am. Phys., 1995, 107, 181-186.
57. Nurtjahja-Tjendraputra, E.; Fu, D.; Phang, J. M.; Richardson, D. R. Iron chelation regulates cyclin D1 expression via the proteasome: a link to iron deficiency-mediated growth suppression. Blood, 2007, 109, 4045-4054.
58. Kulp, K. S.; Green, S. L.; Vulliet, P. R. Iron deprivation inhibits cyclin-dependent kinase activity and decreases cyclin D/CDK4 protein levels in asynchronous MDA-MB-453 human breast cancer cells. Exp. Cell Res., 1996, 229, 60-68.
59. Greijer, A. E.; van der Groep, P.; Kemming, D.; Shvarts, A.; Semenza, G. L.; Meijer, G. A.; van de Wiel, M. A.; Belien, J. A.; van Diest, P. J.; van der Wall, E. Up-regulation of gene expression by hypoxia is mediated predominantly by hypoxia-inducible factor 1 (HIF-1). J. Pathol., 2005, 206, 291-304.
60. Semenza, G. L. Regulation of mammalian O2 homeostasis by hypoxia-inducible factor 1. Annu. Rev. Cell Dev. Biol., 1999, 15, 551-578.
61. Wang, G. L.; Jiang, B. H.; Rue, E. A.; Semenza, G. L. Hypoxiainducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc. Natl. Acad. Sci. USA, 1995, 92, 5510-5514.
62. Ivan, M.; Kondo, K.; Yang, H.; Kim, W.; Valiando, J.; Ohh, M.; Salic, A.; Asara, J. M.; Lane, W. S.; Kaelin, W. G. Jr. HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science, 2001, 292, 464-468.
63. Stockmann, C.; Fandrey, J. Hypoxia-induced erythropoietin production: a paradigm for oxygen-regulated gene expression. Clin. Exp. Pharmacol. Physiol., 2006, 33, 968-979.
64. Bianchi, L.; Tacchini, L.; Cairo, G. HIF-1-mediated activation of transferrin receptor gene transcription by iron chelation. Nucleic Acids Res., 1999, 27, 4223-4227.
65. Le, N. T.; Richardson, D. R. Competing pathways of iron chelation: angiogenesis or anti-tumor activity: targeting different molecules to induce specific effects. Int. J. Cancer, 2004, 110, 468-469.
66. Furukawa, T.; Adachi, Y.; Fujisawa, J.; Kambe, T.; Yamaguchi-Iwai, Y.; Sasaki, R.; Kuwahara, J.; Ikehara, S.; Tokunaga, R.; Taketani, S. Involvement of PLAGL2 in activation of iron deficientand hypoxia-induced gene expression in mouse cell lines. Oncogene, 2001, 20, 4718-4727.
67. Mizutani, A.; Furukawa, T.; Adachi, Y.; Ikehara, S.; Taketani, S. A zinc-finger protein, PLAGL2, induces the expression of a proapoptotic protein Nip3, leading to cellular apoptosis. J. Biol. Chem., 2002, 277, 15851-15858.
68. Kovacevic, Z.; Fu, D.; Richardson, D. R. The iron-regulated metastasis suppressor, Ndrg-1: identification of novel molecular targets. Biochim. Biophys. Acta, 2008, 1783, 1981-1992.
69. van Belzen, N.; Dinjens, W. N.; Diesveld, M. P.; Groen, N. A.; van der Made, A. C.; Nozawa, Y.; Vlietstra, R.; Trapman, J.; Bosman, F. T. A novel gene which is up-regulated during colon epithelial cell differentiation and down-regulated in colorectal neoplasms. Lab Invest., 1997, 77, 85-92.
70. Kovacevic, Z.; Richardson, D. R. The metastasis suppressor, Ndrg-1: a new ally in the fight against cancer. Carcinogenesis, 2006, 27(12), 2355-2366.
71. Bandyopadhyay, S.; Pai, S. K.; Gross, S. C.; Hirota, S.; Hosobe, S.; Miura, K.; Saito, K.; Commes, T.; Hayashi, S.; Watabe, M.; Watabe, K. The Drg-1 gene suppresses tumor metastasis in prostate cancer. Cancer Res., 2003, 63, 1731-1736.
72. Maruyama, Y.; Ono, M.; Kawahara, A.; Yokoyama, T.; Basaki, Y.; Kage, M.; Aoyagi, S.; Kinoshita, H.; Kuwano, M. Tumor growth suppression in pancreatic cancer by a putative metastasis suppressor gene Cap43/NDRG1/Drg-1 through modulation of angiogenesis. Cancer Res., 2006, 66, 6233-6242.
73. Guan, R. J.; Ford, H. L.; Fu, Y.; Li, Y.; Shaw, L. M.; Pardee, A. B. Drg-1 as a differentiation-related, putative metastatic suppressor gene in human colon cancer. Cancer Res., 2000, 60, 749-755.
74. Bandyopadhyay, S.; Pai, S. K.; Hirota, S.; Hosobe, S.; Takano, Y.; Saito, K.; Piquemal, D.; Commes, T.; Watabe, M.; Gross, S. C.; Wang, Y.; Ran, S.; Watabe, K. Role of the putative tumor metastasis suppressor gene Drg-1 in breast cancer progression. Oncogene, 2004, 23, 5675-5681.
75. Hosoi, F.; Izumi, H.; Kawahara, A.; Murakami, Y.; Kinoshita, H.; Kage, M.; Nishio, K.; Kohno, K.; Kuwano, M.; Ono, M. N-myc downstream regulated gene 1/Cap43 suppresses tumor growth and angiogenesis of pancreatic cancer through attenuation of inhibitor of kappaB kinase beta expression. Cancer Res., 2009, 69, 4983-4991.
76. Whitnall, M.; Howard, J.; Ponka, P.; Richardson, D. R. A class of iron chelators with a wide spectrum of potent antitumor activity that overcomes resistance to chemotherapeutics. Proc. Natl. Acad. Sci. USA, 2006, 103, 14901-14906.
77. Buss, J. L.; Torti, F. M.; Torti, S. V. The role of iron chelation in cancer therapy. Curr. Med. Chem., 2003, 10, 1021-1034.
78. Chaston, T. B.; Richardson, D. R. Iron chelators for the treatment of iron overload disease: relationship between structure, redox activity, and toxicity. Am. J. Hematol., 2003, 73, 200-210.
79. Brittenham, G. M.; Griffith, P. M.; Nienhuis, A. W.; McLaren, C. E.; Young, N. S.; Tucker, E. E.; Allen, C. J.; Farrell, D. E.; Harris, J. W. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N. Engl. J. Med., 1994, 331, 567-573.
80. Becton, D. L.; Roberts, B. Antileukemic effects of deferoxamine on human myeloid leukemia cell lines. Cancer Res., 1989, 49, 4809-4812.
81. Blatt, J.; Stitely, S. Antineuroblastoma activity of desferoxamine in human cell lines. Cancer Res., 1987, 47, 1749-1750.
82. Donfrancesco, A.; Deb, G.; Dominici, C.; Pileggi, D.; Castello, M. A.; Helson, L. Effects of a single course of deferoxamine in neuroblastoma patients. Cancer Res., 1990, 50, 4929-4930.
83. Donfrancesco, A.; Deb, G.; Dominici, C.; Angioni, A.; Caniglia, M.; De Sio, L.; Fidani, P.; Amici, A.; Helson, L. Deferoxamine, cyclophosphamide, etoposide, carboplatin, and thiotepa (DCECaT): a new cytoreductive chelation-chemotherapy regimen in patients with advanced neuroblastoma. Am. J. Clin. Oncol., 1992, 15, 319-322.
84. Voest, E. E.; Neijt, J. P.; Keunen, J. E.; Dekker, A. W.; van Asbeck, B. S.; Nortier, J. W.; Ros, F. E.; Marx, J. J. Phase I study using desferrioxamine and iron sorbitol citrate in an attempt to modulate the iron status of tumor cells to enhance doxorubicin activity. Cancer Chemother. Pharmacol., 1993, 31, 357-362.
85. Donfrancesco, A.; De Bernardi, B.; Carli, M.; Mancini, A.; Nigro, M.; De Sio, L.; Casale, F.; Bagnulo, S.; Helson, L.; Deb, G. Deferoxamine followed by cyclophosphamide, etoposide, carboplatin, thiotepa, induction regimen in advanced neuroblastoma: preliminary results. Italian Neuroblastoma Cooperative Group. Eur. J. Cancer, 1995, 31A, 612-615.
86. Kalinowski, D. S.; Richardson, D. R. The evolution of iron chelators for the treatment of iron overload disease and cancer. Pharmacol. Rev., 2005, 57, 547-583.
87. Hallaway, P. E.; Eaton, J. W.; Panter, S. S.; Hedlund, B. E. Modulation of deferoxamine toxicity and clearance by covalent attachment to biocompatible polymers. Proc. Natl. Acad. Sci. USA, 1989, 86, 10108-10112.
88. Poreddy, A. R.; Schall, O. F.; Osiek, T. A.; Wheatley, J. R.; Beusen, D. D.; Marshall, G. R.; Slomczynska, U. Hydroxamatebased iron chelators: combinatorial syntheses of desferrioxamine B analogues and evaluation of binding affinities. J. Comb. Chem., 2004, 6, 239-254.
89. Bergeron, R. J.; Wiegand, J.; McManis, J. S.; Perumal, P. T. Synthesis and biological evaluation of hydroxamate-based iron chelators. J. Med. Chem., 1991, 34, 3182-3187.
90. Ponka, P.; Borova, J.; Neuwirt, J.; Fuchs, O. Mobilization of iron from reticulocytes. Identification of pyridoxal isonicotinoyl hydrazone as a new iron chelating agent. FEBS Lett., 1979, 97, 317-321.
91. Ponka, P.; Borova, J.; Neuwirt, J.; Fuchs, O.; Necas, E. A study of intracellular iron metabolism using pyridoxal isonicotinoyl hydrazone and other synthetic chelating agents. Biochim. Biophys. Acta, 1979, 586, 278-297.
92. Richardson, D.; Ponka, P.; Baker, E. The effect of the iron(III) chelator, desferrioxamine, on iron and transferrin uptake by the human malignant melanoma cell. Cancer Res., 1994, 54, 685-689.
93. Baker, E.; Richardson, D.; Gross, S.; Ponka, P. Evaluation of the iron chelation potential of hydrazones of pyridoxal, salicylaldehyde and 2-hydroxy-1-naphthylaldehyde using the hepatocyte in culture. Hepatology, 1992, 15, 492-501.
94. Richardson, D. R.; Milnes, K. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents II: the mechanism of action of ligands derived from salicylaldehyde benzoyl hydrazone and 2-hydroxy-1-naphthylaldehyde benzoyl hydrazone. Blood, 1997, 89, 3025-3038.
95. Richardson, D. R.; Tran, E. H.; Ponka, P. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents. Blood, 1995, 86, 4295-4306.
96. Becker, E. M.; Lovejoy, D. B.; Greer, J. M.; Watts, R.; Richardson, D. R. Identification of the di-pyridyl ketone isonicotinoyl hydrazone (PKIH) analogues as potent iron chelators and anti-tumour agents. Br. J. Pharmacol., 2003, 138, 819-830.
97. Chaston, T. B.; Watts, R. N.; Yuan, J.; Richardson, D. R. Potent antitumor activity of novel iron chelators derived from di-2-pyridylketone isonicotinoyl hydrazone involves fenton-derived free radical generation. Clin. Cancer Res., 2004, 10, 7365-7374.
98. Mohan, M.; Kumar, M.; Kumar, A.; Madhuranath, P. H.; Jha, N. K. Synthesis, characterization, and antitumor activity of iron(II) and iron(III) complexes of alpha-N-heterocyclic carboxaldehyde thiosemicarbazones. J. Inorg. Biochem., 1988, 32, 239-249.
99. Spingarn, N. E.; Sartorelli, A. C. Synthesis and evaluation of the thiosemicarbazone, dithiocarbazonate, and 2'-pyrazinylhydrazone of pyrazinecarboxaldehyde as agents for the treatment of iron overload. J. Med. Chem., 1979, 22, 1314-1316.
100. Sartorelli, A. C.; Agrawal, K. C.; Tsiftsoglou, A. S.; Moore, E. C. Characterization of the biochemical mechanism of action of alpha (N)-heterocyclic carboxaldehyde thiosemicarbazones. Adv. Enzyme Regul., 1976, 15, 117-139.
101. Sartorelli, A. C.; Booth, B. A. Inhibition of the growth of sarcoma 180 ascites cells by combinations of inhibitors of nucleic acid biosynthesis and the cupric chelate of kethoxal bis-(thiosemicarbazone). Cancer Res., 1967, 27, 1614-1619.
102. Finch, R. A.; Liu, M.; Grill, S. P.; Rose, W. C.; Loomis, R.; Vasquez, K. M.; Cheng, Y.; Sartorelli, A. C. Triapine (3-aminopyridine-2-carboxaldehyde- thiosemicarbazone): A potent inhibitor of ribonucleotide reductase activity with broad spectrum antitumor activity. Biochem. Pharmacol., 2000, 59, 983-991.
103. Finch, R. A.; Liu, M. C.; Cory, A. H.; Cory, J. G.; Sartorelli, A. C. Triapine (3-aminopyridine-2-carboxaldehyde thiosemicarbazone; 3-AP): an inhibitor of ribonucleotide reductase with antineoplastic activity. Adv. Enzyme Regul., 1999, 39, 3-12.
104. Shao, J.; Zhou, B.; Di Bilio, A. J.; Zhu, L.; Wang, T.; Qi, C.; Shih, J.; Yen, Y. A Ferrous-Triapine complex mediates formation of reactive oxygen species that inactivate human ribonucleotide reductase. Mol. Cancer Ther., 2006, 5, 586-592.
105. Chaston, T. B.; Lovejoy, D. B.; Watts, R. N.; Richardson, D. R. Examination of the antiproliferative activity of iron chelators: multiple cellular targets and the different mechanism of action of triapine compared with desferrioxamine and the potent pyridoxal isonicotinoyl hydrazone analogue 311. Clin. Cancer Res., 2003, 9, 402-414.
106. Murren, J.; Modiano, M.; Clairmont, C.; Lambert, P.; Savaraj, N.; Doyle, T.; Sznol, M. Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors. Clin. Cancer Res., 2003, 9, 4092-4100.
107. Ma, B.; Goh, B. C.; Tan, E. H.; Lam, K. C.; Soo, R.; Leong, S. S.; Wang, L. Z.; Mo, F.; Chan, A. T.; Zee, B.; Mok, T. A multicenter phase II trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine((R))) and gemcitabine in advanced nonsmall-cell lung cancer with pharmacokinetic evaluation using peripheral blood mononuclear cells. Invest. New Drugs, 2008, 26, 169-173.
108. Knox, J. J.; Hotte, S. J.; Kollmannsberger, C.; Winquist, E.; Fisher, B.; Eisenhauer, E. A. Phase II study of Triapine in patients with metastatic renal cell carcinoma: a trial of the national cancer institute of canada clinical trials group (NCIC IND.161). Invest. New Drugs, 2007, 25, 471-477.
109. Yuan, J.; Lovejoy, D. B.; Richardson, D. R. Novel di-2-pyridylderived iron chelators with marked and selective antitumor activity: in vitro and in vivo assessment. Blood, 2004, 104, 1450-1458.
110. Whitnall, M.; Howard, J.; Ponka, P.; Richardson, D. R. A class of iron chelators with a wide spectrum of potent antitumor activity that overcomes resistance to chemotherapeutics. Proc. Natl. Acad. Sci. USA, 2006, 103, 14901-14906.
111. Richardson, D. R.; Sharpe, P. C.; Lovejoy, D. B.; Senaratne, D.; Kalinowski, D. S.; Islam, M.; Bernhardt, P. V. Dipyridyl thiosemicarbazone chelators with potent and selective antitumor activity form iron complexes with redox activity. J. Med. Chem., 2006, 49, 6510-6521.
112. Bernhardt, P. V.; Sharpe, P. C.; Islam, M.; Lovejoy, D. B.; Kalinowski, D. S.; Richardson, D. R. Iron chelators of the dipyridylketone thiosemicarbazone class: precomplexation and transmetalation effects on anticancer activity. J. Med. Chem., 2009, 52, 407-415.
113. Kalinowski, D. S.; Yu, Y.; Sharpe, P. C.; Islam, M.; Liao, Y. T.; Lovejoy, D. B.; Kumar, N.; Bernhardt, P. V.; Richardson, D. R. Design, synthesis, and characterization of novel iron chelators: structure-activity relationships of the 2-benzoylpyridine thiosemicarbazone series and their 3-nitrobenzoyl analogues as potent antitumor agents. J. Med. Chem., 2007, 50, 3716-3729.
114. Bergers, G.; Benjamin, L. E. Tumorigenesis and the angiogenic switch. Nat. Rev. Cancer, 2003, 3, 401-410.
115. Gottesman, M. M.; Fojo, T.; Bates, S. E. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat. Rev. Cancer, 2002, 2, 48-58.
116. Ludwig, J. A.; Szakacs, G.; Martin, S. E.; Chu, B. F.; Cardarelli, C.; Sauna, Z. E.; Caplen, N. J.; Fales, H. M.; Ambudkar, S. V.; Weinstein, J. N.; Gottesman, M. M. Selective toxicity of NSC73306 in MDR1-positive cells as a new strategy to circumvent multidrug resistance in cancer. Cancer Res., 2006, 66, 4808-4815.
117. Wu, C. P.; Shukla, S.; Calcagno, A. M.; Hall, M. D.; Gottesman, M. M.; Ambudkar, S. V. Evidence for dual mode of action of a thiosemicarbazone, NSC73306: a potent substrate of the multidrug resistance linked ABCG2 transporter. Mol. Cancer Ther., 2007, 6, 3287-3296.
118. Hall, M. D.; Salam, N. K.; Hellawell, J. L.; Fales, H. M.; Kensler, C. B.; Ludwig, J. A.; Szakacs, G.; Hibbs, D. E.; Gottesman, M. M. Synthesis, activity, and pharmacophore development for isatinbeta-thiosemicarbazones with selective activity toward multidrugresistant cells. J. Med. Chem., 2009, 52, 3191-3204.
119. Yiakouvaki, A.; Savovic, J.; Al-Qenaei, A.; Dowden, J.; Pourzand, C. Caged-iron chelators a novel approach towards protecting skin cells against UVA-induced necrotic cell death. J. Invest. Dermatol., 2006, 126, 2287-2295.
120. Zhong, J. L.; Yiakouvaki, A.; Holley, P.; Tyrrell, R. M.; Pourzand, C. Susceptibility of skin cells to UVA-induced necrotic cell death reflects the intracellular level of labile iron. J. Invest. Dermatol., 2004, 123, 771-780.
121. Flora, K.; Hahn, M.; Rosen, H.; Benner, K. Milk thistle (Silybum marianum) for the therapy of liver disease. Am. J. Gastroenterol., 1998, 93, 139-143.
122. Jacobs, B. P.; Dennehy, C.; Ramirez, G.; Sapp, J.; Lawrence, V. A. Milk thistle for the treatment of liver disease: a systematic review and meta-analysis. Am. J. Med., 2002, 113, 506-515.
123. Garcia-Maceira, P.; Mateo, J. Silibinin inhibits hypoxia-inducible factor-1alpha and mTOR/p70S6K/4E-BP1 signalling pathway in human cervical and hepatoma cancer cells: implications for anticancer therapy. Oncogene, 2009, 28, 313-324.
124. Li, L.; Gao, Y.; Zhang, L.; Zeng, J.; He, D.; Sun, Y. Silibinin inhibits cell growth and induces apoptosis by caspase activation, downregulating survivin and blocking EGFR-ERK activation in renal cell carcinoma. Cancer Lett., 2008, 272, 61-69.
125. Gharagozloo, M.; Khoshdel, Z.; Amirghofran, Z. The effect of an iron (III) chelator, silybin, on the proliferation and cell cycle of Jurkat cells: a comparison with desferrioxamine. Eur. J. Pharmacol., 2008, 589, 1-7.
126. Cui, W.; Gu, F.; Hu, K. Q. Effects and mechanisms of silibinin on human hepatocellular carcinoma xenografts in nude mice. World J. Gastroenterol., 2009, 15, 1943-1950.
127. Singh, R. P.; Raina, K.; Sharma, G.; Agarwal, R. Silibinin inhibits established prostate tumor growth, progression, invasion, and metastasis and suppresses tumor angiogenesis and epithelialmesenchymal transition in transgenic adenocarcinoma of the mouse prostate model mice. Clin. Cancer Res., 2008, 14, 7773-7780.
128. Tyagi, A.; Singh, R. P.; Ramasamy, K.; Raina, K.; Redente, E. F.; Dwyer-Nield, L. D.; Radcliffe, R. A.; Malkinson, A. M.; Agarwal, R. Growth inhibition and regression of lung tumors by silibinin: modulation of angiogenesis by macrophage-associated cytokines and nuclear factor-kappaB and signal transducers and activators of transcription 3. Cancer Prev. Res. (Phila Pa), 2009, 2, 74-83.
129. Chittezhath, M.; Deep, G.; Singh, R. P.; Agarwal, C.; Agarwal, R. Silibinin inhibits cytokine-induced signaling cascades and downregulates inducible nitric oxide synthase in human lung carcinoma A549 cells. Mol. Cancer Ther., 2008, 7, 1817-1826.
130. Borsari, M.; Gabbi, C.; Ghelfi, F.; Grandi, R.; Saladini, M.; Severi, S.; Borella, F. Silybin, a new iron-chelating agent. J. Inorg. Biochem., 2001, 85, 123-129.
131. Hatcher, H.; Planalp, R.; Cho, J.; Torti, F. M.; Torti, S. V. Curcumin: from ancient medicine to current clinical trials. Cell Mol. Life Sci., 2008, 65, 1631-1652.
132. Jiao, Y.; Wilkinson, J. t.; Di, X.; Wang, W.; Hatcher, H.; Kock, N. D.; D'Agostino, R., Jr.; Knovich, M. A.; Torti, F. M.; Torti, S. V. Curcumin, a cancer chemopreventive and chemotherapeutic agent, is a biologically active iron chelator. Blood, 2009, 113, 462-469.
133. Kunnumakkara, A. B.; Diagaradjane, P.; Anand, P.; Kuzhuvelil, H. B.; Deorukhkar, A.; Gelovani, J.; Guha, S.; Krishnan, S.; Aggarwal, B. B. Curcumin sensitizes human colorectal cancer to capecitabine by modulation of cyclin D1, COX-2, MMP-9, VEGF and CXCR4 expression in an orthotopic mouse model. Int. J. Cancer, 2009.
134. Ligeret, H.; Barthelemy, S.; Zini, R.; Tillement, J. P.; Labidalle, S.; Morin, D. Effects of curcumin and curcumin derivatives on mitochondrial permeability transition pore. Free Radic. Biol. Med., 2004, 36, 919-929.
135. Arbiser, J. L.; Klauber, N.; Rohan, R.; van Leeuwen, R.; Huang, M. T.; Fisher, C.; Flynn, E.; Byers, H. R. Curcumin is an in vivo inhibitor of angiogenesis. Mol. Med., 1998, 4, 376-383.
136. Gururaj, A. E.; Belakavadi, M.; Venkatesh, D. A.; Marme, D.; Salimath, B. P. Molecular mechanisms of anti-angiogenic effect of curcumin. Biochem. Biophys. Res. Commun., 2002, 297, 934-942.
137. Thaloor, D.; Singh, A. K.; Sidhu, G. S.; Prasad, P. V.; Kleinman, H. K.; Maheshwari, R. K. Inhibition of angiogenic differentiation of human umbilical vein endothelial cells by curcumin. Cell Growth Differ., 1998, 9, 305-312.
138. Jiao, Y.; Wilkinson, J. t.; Christine Pietsch, E.; Buss, J. L.; Wang, W.; Planalp, R.; Torti, F. M.; Torti, S. V. Iron chelation in the biological activity of curcumin. Free Radic. Biol. Med., 2006, 40, 1152-1160.
139. Richardson, D. R.; Ponka, P. The molecular mechanisms of the metabolism and transport of iron in normal and neoplastic cells. Biochim. Biophys. Acta, 1997, 1331, 1-40.